Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).

被引：0
|
作者：
Berghoff, A.
Bartsch, R.
Bago-Horvath, Z.
Dubsky, P. C.
Rudas, M.
Pluschnig, U.
Wiltschke, C.
Gnant, M.
Steger, G. G.
Zielinski, C.
机构：
[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
[2] Med Univ Vienna, Div Clin Oncol, Dept Med 1, Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, Vienna, Austria
[4] Med Univ Vienna, Dept Surg, Vienna, Austria
[5] Med Univ Vienna, Vienna, Austria
[6] Med Univ Vienna, Ctr Comprehens Canc, Dept Surg, Vienna, Austria
[7] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
572
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer
    Munster, Pamela N.
    Miller, Kathy
    Krop, Ian E.
    Dhindsa, Navreet
    Reynolds, Joe
    Geretti, Elena
    Niyikiza, Clet
    Nielsen, Ulrik
    Hendriks, Bart
    Wickham, Thomas J.
    Moyo, Victor M.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study
    Marczyk, Vicente Rodrigues
    Rosa, Daniela Dornelles
    Maia, Ana Luiza
    Goemann, Iuri Martin
    CLINICAL BREAST CANCER, 2022, 22 (05) : 418 - 423
  • [23] Outcome of HER2-Positive (HER2+) Metastatic Breast Cancer Patients (MBC) Treated with Trastuzumab (T): An Institutional Based Review
    Guilhaume, M-N
    Dieras, V
    Fall, M.
    Pierga, J-Y
    Beuzeboc, P.
    Cottu, P. H.
    Simondi, C.
    Courbard, M.
    Mignot, L.
    Livartowski, A.
    CANCER RESEARCH, 2009, 69 (24) : 801S - 801S
  • [24] TNFα induces multiresistance to HER2-targeted TNFα induces multiresistance to HER2-targeted therapies in HER2-positive breast cancer
    Mercogliano, Maria F.
    De Martino, Mara
    Bruni, Sofia
    Venturutti, Leandro
    Rivas, Martin
    Amasino, Matias
    Proietti, Cecilia J.
    Elizalde, Patricia V.
    Schillaci, Roxana
    CANCER RESEARCH, 2017, 77
  • [25] HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
    Erickson, Anders W.
    Ghodrati, Farinaz
    Habbous, Steven
    Jerzak, Katarzyna J.
    Sahgal, Arjun
    Ahluwalia, Manmeet S.
    Das, Sunit
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [26] Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
    Michiels, S.
    Pugliano, L.
    Marguet, S.
    Grun, D.
    Barinoff, J.
    Cameron, D.
    Cobleigh, M.
    Di Leo, A.
    Johnston, S.
    Gasparini, G.
    Kaufman, B.
    Marty, M.
    Nekljudova, V.
    Paluch-Shimon, S.
    Penault-Llorca, F.
    Slamon, D.
    Vogel, C.
    von Minckwitz, G.
    Buyse, M.
    Piccart, M.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1029 - 1034
  • [27] Shorter Overall Survival (OS) in HER2-positlve (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC)
    Gori, S.
    Sidoni, A.
    Colozza, M.
    Mameli, M. G.
    Fenocchio, D.
    Minenza, E.
    Foglietta, J.
    Stocchi, L.
    De Angelis, V.
    Crino, L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 287 - 287
  • [28] A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy
    Brufsky, Adam
    Zulfiqar, Malik
    Peguero, Julio
    Lathrop, Kate
    Bhat, Gajanan
    Lebel, Francois
    CANCER RESEARCH, 2021, 81 (04)
  • [29] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Delayed initiation of HER2-targeted therapy (HER2Tx) is associated with a higher risk of relapse for early stage (ES) HER2-positive (HER2+) breast cancer (BrCa)
    Gullo, G.
    Bose, R.
    Walsh, N.
    Maltese, M.
    Fennelly, D.
    Walshe, J.
    Ballot, J.
    Crown, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345